AZD6738 (ceralasertib), an ATR inhibitor that is useful as a monotherapy or synergizes with Olaparib or carboplatin, results in robust tumor retardation through the modulation of ATR/ATM/DNA-PK signaling and HR repair13. The gene discussed is ATR; the disease is neoplasm.